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Objectives: To estimate health and social care resource use in treating individu-
als with Fragile X Syndrome (FXS) in Canada and the United Kingdom (UK). FXS is 
the most common inherited form of intellectual disability (ID) worldwide; however 
its impact on resource use is not well documented. MethOds: Delphi panels 
were formed to generate consensus-based estimates of resource use. Panelists 
from multiple disciplines were recruited (7 panelists in Canada, 6 in UK) and a 
questionnaire developed to obtain estimates from each panelist by 2 age groups, 2 
severity levels and 24 service types for each of 9 items from the Aberrant Behavior 
Checklist (ABC) a proxy completed instrument to rate maladaptive behaviors of 
individuals with ID. A factor weight was estimated to differentiate costs by gender 
and a self-declared confidence score (1 – 5) was reported for each ABC item. Mean 
total service counts and coefficients of variation (CV) were calculated to assess 
variance between panelists and between rounds. Initial results were reviewed 
with panelists in a facilitated group discussion after which the questionnaire was 
repeated. Final data were based on the second round of estimation. Results: 
Comprehensive resource data were collected for both countries. There was lower 
variance and higher confidence in both countries in round 2 compared to 1. 
Rounds 1 and 2 means (CV) for Canada were [6,723 (0.69) 8,575 (0.52)] and for 
UK were [6,953 (0.96) 6,023 (0.76)]. The average level of self-declared confidence 
increased from 2.6 to 3.3 in Canada and from 2.6 to 2.8 in the UK. cOnclusiOns: 
The study generated comprehensive resource use data for treating individuals 
with FXS in Canada and the UK. Credible and validated estimates were generated 
through group discussion and refinement of initial estimates. The resulting data 
will be important in performing economic evaluations of treatments for patients 
with FXS.
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Objectives: To gain an understanding of the impact of bariatric surgery on the 
current medical management of obese patients. MethOds: The EGB database is 
a 1/97 representative sample (around 600,000 individuals) of the national claims 
database covering the whole French population including outpatients and inpa-
tient care. Adult patients treated for the first time over the period 01/01/2007 to 
31/12/2009 by bariatric surgery were identified through related procedures and 
obesity ICD-10 codes. A cohort of patients was constituted with a 2-year follow-up 
before and after the index procedure date (T). Reimbursed medical consumption 
over this 4-year period was recorded and presence of co-morbidities was identified 
through ICD-10 codes, reimbursement of specific drugs or procedures. Results: 
A total of 350 patients meeting the selection criteria were identified in the data-
base with a mean age of 38.9 (+/- 11.3) years, 83.4% female and 69.7% had a BMI 
in the range 40-50. The distribution of patients according to bariatric procedure 
was gastric banding (62.6%), gastric by-pass (19.7%), sleeve gastrectomy (16.6%) 
and bilio-pancreatic diversion (1.1%). The annual per capita reimbursed health 
expenses evolved from 2.633€ (+/-3.124€ ) in Year (T-2), to 3.557€ (+/-3.380€ ) in Year 
(T-1), to 4.240€ (+/-3.840€ ) in Year (T+1) (excluding procedure cost) to 3.755€ (+/-
5.037€ ) in Year (T+2). In 39% of patients those costs decreased between T-2 and 
T+2, (> 5%) and the only two variables significantly explaining this decrease were 
the reduction of consumption for anti-Diabetes and/or anti-Hypertension drugs. 
Most items of medical consumption increased over the period pre and post proce-
dure but started to decrease in Year T+2. cOnclusiOns: The visits for preparing 
bariatric surgery were probably an opportunity for those patients to benefit from 
a general check-up which has generated extra short term medical consumption. 
Additional research with longer follow up could better capture the benefits of 
bariatric surgery on medical consumption.
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Objectives: To assess treatment cost and duration (months) of major cytoge-
netic response (MCyR) using ponatinib in patients intolerant or resistant to 2G 
TKI, compared to treating with only 2G TKIs, in patients with Ph+ leukemia, in 
Italy. MethOds: A 3-year Markov model with 1-year cycles simulated patients 
with Ph+ leukemia to estimate outcomes in those eligible for ponatinib therapy, 
defined as 1) 2G TKI-resistant, 2) 2G TKI-intolerant if imatinib is not clinically 
appropriate, or 3) with T315I mutation. Eligible patients received treatment 
sequences including 2G TKIs and ponatinib in the ponatinib arm and 2G TKI 
only in the comparator arm. Patients without MCyR by 12 months were switched 
to the next therapy line until TKI options were exhausted, then to best sup-
portive care. MCyR rates for 2G TKI or ponatinib were estimated from clinical 
trial data and expert opinion. Patients were assumed to accrue MCyR months 
until estimated treatment failure. Monthly treatment costs reflect approved 
EU dosing and list prices; cost of ponatinib was assumed equivalent to the 
US. Results: We estimated 184, 280, and 360 ponatinib-eligible patients in 
years 1-3, respectively. Treating ponatinib-eligible Ph+ leukemia patients with 
2G TKIs yielded a 3-year cost of € 58.51 million and a total of 2,536 months in 
MCyR, at an average cost of € 23,068/MCyR month. Using ponatinib in eligible 
patients cost € 79.54 million and provided 5,649 months in MCyR, at an average 
cost of € 14,079/MCyR month. cOnclusiOns: The treatment strategy includ-
primary care (range: 1.0%–9.4%) than in general hospitals (range: 5.8%–43.3%), and 
highest in specialist nephrology settings (range: 16.0%–97.6%). Also, prevalence rates 
increased with the CKD stage (1–2: 14.1%–27.9%; 3: 25.5%–91.1%; 4: 36.0%–85.5%; 5: 
97.6%). The cost of managing anaemia per patient per year varied across studies 
from £2,616 (2006–2007 Great British Pounds; GBP) to £3,740 (2006 GBP) in the UK, to 
€ 5,617 in France (cost year not reported). One study reported that the overall cost of 
managing anaemia was highest in patients with CKD Stage 3 compared with other 
stages (3: £4,162,056 vs. 4–5: £243,288; 2006–2007 GBP). Another study reported higher 
costs per patient per annum for individuals with lower haemoglobin (Hb) levels (Hb 
> 12 g/dL: € 2,418; Hb < 10 g/dL: € 13,005; cost year not reported). Among patients with 
CKD, those with anaemia were more likely to be hospitalised (61% vs. 50% of those 
without anaemia). cOnclusiOns: Anaemia is a highly prevalent condition in CKD 
across treatment settings in Europe, and the limited evidence available suggests it 
is associated with a substantial economic burden.
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Objectives: Peripheral neuropathic pain (PNP) implies a significant economic 
burden that results in major health care and indirect costs. The aim of the present 
analysis was modelling the association and predictive value of pain intensity on 
costs and resources utilization (health care and non-health resources) in patients 
with chronic PNP treated in routine clinical practice conditions in Spain. MethOds: 
Secondary economic analysis based on data from a multicenter, observational and 
prospective cost-of-illness study in patients with chronic PNP refractory to previous 
treatment. Data on resources utilization and pain intensity was collected at baseline 
and 12 weeks after starting a new treatment. Pain intensity was measured using the 
0-100 mm Visual Analogue Scale (VAS) of the Short Form McGill Pain Questionnaire. 
Univariate and multivariate linear regression models were fitted to identify inde-
pendent predictors of costs and health care and non-health care resources utiliza-
tion. Results: A total of 1703 patients were included in the current analysis. Pain 
intensity was an independent predictor of total costs ([Total costs(Euros)] = 35.6 x 
[VAS pain intensity] + 214.5; coefficient of determination [R2]= 0.19, p< 0.001), direct 
costs ([Direct costs(Euros)] = 10.8 x [VAS pain intensity] + 257.7; R2= 0.06, p< 0.001) 
and indirect costs ([Indirect costs(Euros)] = 24.8 x [VAS pain intensity] – 43.4; R2= 0.19, 
p< 0.001) related to chronic PNP in the univariate analysis. Pain intensity remain 
significantly associated with total costs, direct costs and indirect costs after adjust-
ment by other covariates in the multivariate analysis (p< 0.001). The impact of pain 
intensity on health care and non-health care resources utilization accounted for 
such findings. cOnclusiOns: Pain intensity predicts the health care and non-
health care resources utilization, and costs related to chronic PNP. Management of 
patients with drugs associated with a higher reduction of pain intensity will have 
a greater impact on the economic burden of that condition.
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Objectives: Pemphigus and pemphigoid are a rare group of potentially fatal dis-
eases, causing blistering on mucosal and epidermal surfaces. Long-term treatment 
with systemic corticosteroids and immunosuppressive agents such as intravenous 
immunoglobulin (IVIg) are usually required. Rituximab (RTX) is increasingly being 
used for autoimmune bullous dermatoses (AIBD) and has shown to be effective, 
however, in Canada, RTX is not approved for AIBD. Given the potential cost associ-
ated with the use of RTX, there is a need to quantify the issues around accessing 
it for AIBD patients. MethOds: Resources (e.g., treatment, lab costs, procedures, 
access to health care providers) associated with 89 AIBD patients were collected 
and quantified 6 months prior and 6 months post RTX initiation. Costs of adverse 
events secondary to standard treatment (e.g., steroid adverse effects such as dia-
betes, cataracts, osteoporosis etc) and costs of medications used to prevent steroid 
adverse effects (e.g., proton pump inhibitors, bisphosphonates) were not calculated. 
Unit costs (2013 $CAN) were applied to the resources. Overall cohort costs pre and 
post RTX, as well as cost per patient, were calculated. Cost drivers were identi-
fied. Results: The overall cohort cost for 6 months pre-RTX was $3.7million (M), 
and 6 months post was $2.6M (30.3% decrease). IVIg was shown to be the main 
cost driver. 6 months pre-RTX, 157 months of IVIG was used ($3.6M) compared to 
71 months ($1.6M) 6 months post. The cost associated with access to health care 
resources significantly reduced from $46,715 vs. $22,978, and fewer visits to the 
dermatologist were required (377 vs. 256 visits). A decrease was also observed in 
the cost of specialist consultations required ($5,807 vs. $3,234) and other treatment/
medication use ($64,548 vs. $48,045). The cost per patient decreased ($41,497 vs. 
$28,923). cOnclusiOns: RTX is effective in reducing the number of resources and 
costs associated with treatment of AIBD.
PSY28
health and SocIal care reSource uSe BY IndIvIdualS wIth fragIle x 
SYndrome: reSultS of two delPhI PanelS
Barry S.J1, London P.2, Bostock T.1, Adlard N.3, Lakhdari K.4, Aubertin G.5, Burge P.6, Corbin J.F.7, 
Gagnon S.7, Hassiotis A.8
1Optum, Burlington, ON, Canada, 2Optum, Chicago, IL, USA, 3Novartis Pharmaceuticals UK, 
Surrey, UK, 4Novartis Pharmaceuticals Canada, Montreal, QC, Canada, 5University of British 
Columbia, Victoria, BC, Canada, 6Queen’s University, Kingston, ON, Canada, 7University de 
Sherbrooke, Sherbrooke, QC, Canada, 8University College London, London, UK
